Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5448-5453

  Heist, Rebecca Suk ^a,b   Marshall, Ariela L ^b   Liu, Geoffrey ^a,b   Zhou, Wei ^b   Su, Li ^b   Neuberg, Donna ^b   Lynch, Thomas J ^a   Wain, John ^a   Christiani, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; STROMELYSIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 33749355265     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0262     Document Type: Article

References (33)

1. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Orthod 2004;22:7019.
2. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New Engl J Med 2004;350 351-60.
3. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. New Engl J Med 2005;352:2589-97.
4. Lee MH, Murphy G. Matrix metalloproteinases at a glance. J Cell Sci 2004;117:4015-6.
5. De Souza AP, Line SRP. The biology of matrix metalloproteinases. Rev FOB 2002;10:1-6.
6. Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anti-cancer therapy: status and prospects. Emerg Ther Targets 2000;4:609-33.
7. Stetler-Stevenson WG. Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994;14:259-68.
8. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43:542-51.
9. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
10. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clinical Cancer Res 2000;6:4823-30.
11. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000;19:623-9.
12. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5.
13. Ye S, Ericksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055-60.
14. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human metalloproteinase-2 gene: role of Sp1 in allele specific transcriptional regulation. J Biol Chem 2001;276:7549-58.
15. Jormsjo SYS, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000;86:998-1003.
16. Su L, Zhou W, Park S, et al. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:567-70.
17. Zhou Y, Yu C, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005;26:1117-21.
18. Fang S, Jin X, Wang K, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005;26:481-6.
19. Benjamini Y, Hochberg Y. Controlling the false discover rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:290-300.
20. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 2006;27:1024-9.
21. Zhu Y, Spitz MR, Lei L, et al. A single nucleotide polymorphism in the matrix metalloproteinase 1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825-9.
22. Shin A, Cai Q, Shu X, et al. Genetic polymorphisms in the matrix metalloproteinase 12 gene and breast cancer risk and survival: the Shanghai Breast Cancer Study. Breast Cancer Res 2005;7:R506-12.
23. Zinzindohoue F, Lecomte T, Ferraz JM, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11:594-9.
24. Six L, Grimm C, Leodolter S, et al. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. Gynecol Oncol 2006;100:506-10.
25. Przybylowska K, Kluczna A, Zadronzny M, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006;95:65-72.
26. Cho NH, Hong KP, Hong SH, et al. MMP expression profiling in recurred stage IB lung cancer. Oncogene 2004;23:845-51.
27. Hofmann HS, Hansen G, Richter G, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer. Clin Cancer Res 2005;11:1086-92.
28. Lin TS, Chiou SH, Wang LS, et al. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 2004;12:717-23.
29. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.
30. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
31. Yamaguchi NH, Lichtenfels AJ, Demarchi LMM, et al. Cox-2, MMP-9, and Noguchi classification provide additional prognostic information about adenocarcinoma of the lung. Anat Pathol 2004;121:78-86.
32. Pinto CA, de Oliveira Carvalho PE, Antonangelo L, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9:3098-104.
33. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003;103:647-51.